Schonfeld Strategic Advisors LLC Makes New Investment in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Schonfeld Strategic Advisors LLC purchased a new position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 365,200 shares of the company's stock, valued at approximately $6,117,000. Schonfeld Strategic Advisors LLC owned 0.28% of Centessa Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of CNTA. State Street Corp acquired a new position in Centessa Pharmaceuticals in the 3rd quarter valued at approximately $777,000. Franklin Resources Inc. raised its stake in shares of Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock valued at $38,360,000 after purchasing an additional 1,145,823 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in Centessa Pharmaceuticals in the third quarter worth $4,305,000. JPMorgan Chase & Co. boosted its stake in Centessa Pharmaceuticals by 1,969.2% during the third quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company's stock worth $2,173,000 after buying an additional 129,335 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Centessa Pharmaceuticals by 68.7% in the 3rd quarter. Geode Capital Management LLC now owns 56,597 shares of the company's stock valued at $905,000 after buying an additional 23,058 shares during the period. 82.01% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating for the company. Guggenheim reaffirmed a "buy" rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Morgan Stanley reissued an "overweight" rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, Piper Sandler assumed coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $27.71.

Insiders Place Their Bets

In other news, insider Karen M. Anderson sold 30,526 shares of the business's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $19.03, for a total transaction of $580,909.78. Following the completion of the sale, the insider now owns 54,322 shares in the company, valued at $1,033,747.66. The trade was a 35.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Saurabh Saha sold 14,656 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $12.29, for a total value of $180,122.24. Following the transaction, the chief executive officer now directly owns 261,361 shares in the company, valued at $3,212,126.69. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 202,353 shares of company stock valued at $3,286,478. Insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Price Performance

Shares of CNTA traded down $0.04 on Monday, hitting $13.57. The company's stock had a trading volume of 419,061 shares, compared to its average volume of 615,641. The company has a market capitalization of $1.81 billion, a PE ratio of -8.87 and a beta of 1.53. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09. The company has a 50 day moving average price of $14.17 and a 200 day moving average price of $15.78. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.04. On average, research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.